GLP-1 activity includes: Enhancing insulin secretion in a glucose-dependent manner Suppressing glucagon release, which would otherwise raise blood sugar Slowing gastric emptying to better regulate digestion Promoting satiety, which can reduce food intake GLP1-S in Research In laboratory research, GLP1-S is investigated for its ability to influence glucose homeostasis, appetite regulation, and energy balance
Long-term pharmacological treatment such as GLP-1 medications might be a viable solution to sustain progress and achieve desired outcomes
Pharmacologically mediated reductions in maternal body weight gain and food consumption were observed at all dose levels
PMID 31579821
Sergey Terushkin, MD, FACS Key Takeaways: Mounjaro (tirzepatide) targets GIP + GLP-1 receptors , while Ozempic (semaglutide) targets GLP-1 only Clinical studies show greater average weight loss with tirzepatide in many patients Both medications require BMI 30 or 27 with weight-related conditions Common side effects include nausea, GI discomfort, and appetite changes , usually improving with dose adjustment Insurance coverage varies more common for diabetes than weight loss Prescription required treatment must be doctor-guided and medically supervised If you are deciding between Mounjaro and Ozempic for weight loss in 2026, the key difference is that tirzepatide (Mounjaro) activates two metabolic pathways (GIP + GLP-1), while semaglutide (Ozempic) activates one (GLP-1) which may impact weight loss outcomes and tolerability